Real-World Evidence Likely Untainted By COVID-19 Journal Article Debacle

Retraction of Lancet, NEJM studies does not signal doubts about the utility of RWE for evaluating drug efficacy and safety; instead, it highlights importance of transparency, validation and audit trails for real-world datasets, and lack of familiarity with RWE methods among medical journal peer reviewers, experts say.

PS2006_Caution Tape_1038420718_1200.jpg
Researchers and journal editors may want to proceed with caution when a real-world dataset seems too good to be true. • Source: Shutterstock

The prominent retraction of two observational studies on COVID-19 is unlikely to permanently taint interest in leveraging real-word evidence about drug efficacy and safety.

The withdrawal of the studies in the Lancet and New England Journal of Medicine, both led by Brigham and Women’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Real-World Evidence

More from Clinical Trials